PCDH8 Antibody (JK-19): sc-81817
- PCDH8 Antibody (JK-19) is a mouse monoclonal IgG1 κ, cited in 1 publications, provided at 100 µg/ml
- raised against recombinant PCDH8 of human origin
- recommended for detection of PCDH8 of human origin by WB, IP, IF, IHC(P) and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for PCDH8 Antibody (JK-19). This work is in progress.
PCDH8 Antibody (JK-19) is a mouse monoclonal IgG1 antibody that detects protocadherin-8 in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). PCDH8, also known as Arcadlin or PAPC, is a crucial 1,070 amino acid single-pass type I membrane protein characterized by six cadherin domains, which are essential for mediating cell-cell adhesion in the central nervous system. PCDH8 is predominantly localized to the cell membrane and specifically expressed in both fetal and adult brain tissues, highlighting PCDH8′s significant role in establishing and maintaining neuronal connections. Anti-PCDH8 antibody (JK-19) has revealed that PCDH8 is often inactivated or silenced in breast cancer, suggesting a protective role against tumorigenesis. Additionally, PCDH8 exists in two isoforms from alternative splicing, differing in cytoplasmic tails, which may influence functional properties and interactions within the cellular environment. PCDH8 monoclonal antibody (JK-19) serves as an invaluable tool for researchers investigating cell adhesion dynamics and protocadherin implications in cancer biology and neurodevelopment.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
PCDH8 Antibody (JK-19) References:
- PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. | Yu, JS., et al. 2008. Oncogene. 27: 4657-65. PMID: 18408767
- Aberrant methylation of PCDH8 is a potential prognostic biomarker for patients with clear cell renal cell carcinoma. | Lin, YL., et al. 2014. Med Sci Monit. 20: 2380-5. PMID: 25416427
- Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer. | Lin, YL., et al. 2014. J Exp Clin Cancer Res. 33: 68. PMID: 25927589
- PCDH8 is Frequently Inactivated by Promoter Hypermethylation in Liver Cancer: Diagnostic and Clinical Significance. | Zhang, C., et al. 2016. J Cancer. 7: 446-52. PMID: 26918058
- PCDH8 inhibits glioma cell proliferation by negatively regulating the AKT/GSK3β/β-catenin signaling pathway. | Zong, Z., et al. 2017. Oncol Lett. 14: 3357-3362. PMID: 28927088
- Low Expression of Protocadherin-8 Promotes the Progression of Ovarian Cancer. | Cao, Y., et al. 2018. Int J Gynecol Cancer. 28: 346-354. PMID: 29324532
- MicroRNA-124-3p inhibited progression of nasopharyngeal carcinoma by interaction with PCDH8 and the inactivation of PI3K/AKT/mTOR pathway. | Ye, J., et al. 2021. J Cancer. 12: 4933-4944. PMID: 34234863
- Retracted Article: Overexpression of PCDH8 inhibits proliferation and invasion, and induces apoptosis in papillary thyroid cancer cells. | Chang, L., et al. 2018. RSC Adv. 8: 18030-18037. PMID: 35542088
- PCDH8 participates in the growth process of colorectal cancer cells by regulating the AKT/GSK3β/β-catenin signaling pathway. | Wu, S., et al. 2022. Tissue Cell. 78: 101864. PMID: 35907345
- PCDH8 is a novel prognostic biomarker in thyroid cancer and promotes cell proliferation and viability. | Yang, R., et al. 2024. Funct Integr Genomics. 24: 35. PMID: 38368303
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PCDH8 Antibody (JK-19) | sc-81817 | 100 µg/ml | $339.00 |